Literature DB >> 8541531

A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library.

H M Griffin1, W H Ouwehand.   

Abstract

IgG alloantibodies to polymorphic platelet glycoproteins (GPs) are known to be responsible for severe thrombocytopenia in the neonate and after transfusion. Platelet GPIIIa can have either a leucine or a proline at residue 33. The most immunogenic platelet alloantigen in thrombocytopenia is the leucine 33 form of GPIIIa. Here, we have generated human monoclonal antibody fragments that are specific for the leucine and not the proline form of GPIIIa and can inhibit the binding of polyclonal human IgG alloantibodies to GPIIIa leucine 33 on platelets. The antibody fragments were selected from a library of single chain Fv fragments displayed on the surface of filamentous phage. The VH gene repertoire was derived from the peripheral blood lymphocytes of an alloimmunized individual and recombined with a VL gene repertoire from a nonimmune source. Antibodies such as these, which are able to distinguish between two variant forms of a native antigen and which have been unobtainable by conventional hybridoma technology, have both diagnostic and potential therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541531

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Management of severe alloimmune thrombocytopenia in the newborn.

Authors:  W H Ouwehand; G Smith; E Ranasinghe
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  The analysis and quantification of a clonal B cell response in a hyperimmunized anti-D donor.

Authors:  S E Dohmen; O J H M Verhagen; S M de Groot; L M Stott; R C Aalberse; S J Urbaniak; C E van der Schoot
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology.

Authors:  Julien Thibaut; Yves Mérieux; Dominique Rigal; Germain Gillet
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

4.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

5.  Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alphavbeta3 integrin conformers.

Authors:  Tracy Raymond; Elena Gorbunova; Irina N Gavrilovskaya; Erich R Mackow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

6.  High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1).

Authors:  Huiying Zhi; Maria Therese Ahlen; Aye Myat Myat Thinn; Hartmut Weiler; Brian R Curtis; Bjørn Skogen; Jieqing Zhu; Peter J Newman
Journal:  Blood Adv       Date:  2018-11-13

7.  Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.

Authors:  C M Radder; H Beekhuizen; H H H Kanhai; A Brand
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

9.  Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets.

Authors:  Kathryn L Armour; Cheryl S Smith; Craig P Turner; Christopher M Kirton; Anthony M Wilkes; Andrew G Hadley; Cedric Ghevaert; Lorna M Williamson; Michael R Clark
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.